Lennox Gastaut Syndrome Market Segmentation:
- By Drug Class
- GABA modulators
- Sodium channel blockers
- Calcium channel blockers
- SV2A modulators
- Benzodiazepines
- Others
- By Route of Administration
- Oral
- Intravenous
- Intranasal
- Transdermal
- Others
- By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Others
- By Age Group
- Infants & Toddlers (0 - 2 years)
- Children (3 - 12 years)
- Adolescents (13 - 18 years)
- Adults (>18 years)
- By Treatment Type
- Monotherapy
- Adjunctive/Combination Therapy
- Vagus Nerve Stimulation
- Ketogenic Diet
- Others
- By Region
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East & Africa
Frequently Asked Questions
The current market size of the Lennox Gastaut Syndrome industry is USD 560 million in 2023.
Increasing LGS prevalence, new drug development, emerging gene and stem cell therapies, rising pediatric epilepsy cases globally.
The key factors hampering the growth of the Lennox Gastaut Syndrome Market are lack of curative therapies, high cost of treatment, side effects of drugs, low awareness among physicians, misdiagnosis and delayed diagnosis.
The leading component segment in the Lennox Gastaut Syndrome Market is GABA modulators.
The major players operating in the Lennox Gastaut Syndrome Market are Eisai, Lundbeck, GW Pharmaceuticals, Zogenix, and Supernus Pharmaceuticals.
The CAGR will be 11.8% and the market size will reach USD 1,366.9 million by 2031.
The key drivers of the Lennox Gastaut Syndrome Market are increasing prevalence, new drug development, emerging gene therapies, improved diagnosis, combination therapies, rising awareness, and favorable government policies.